Home > Insider Trading > Filing (0000899243-23-018762)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1113148	Infinity Pharmaceuticals Inc.	INFI	Pharmaceutical Preparations (2834)	330655706

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1375124	Q Adelene Perkins	C/O Infinity Pharmaceuticals, Inc. 1100 Massachusetts Avenue, Floor 4 Cambridge MA 02138		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-09-09	768,133	$0.00	1,585,487	No	4	M	Direct
Common Stock	Disposition	2023-09-12	410,196	$0.07	1,175,291	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Unit	Disposition	2023-09-09	768,133	$0.00	768,133	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	16,447	Indirect	401(K)

Footnotes

Restricted stock units ("RSUs") convert into Common Stock of the issuer on a one-for-one basis. This transaction represents the settlement of RSUs in shares of Common Stock on their vesting date.
Pursuant to a binding contract entered into between the issuer and the reporting person on August 15, 2022, this represents the shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the RSUs listed in Table II. Such binding contract is intended to be consistent with the affirmative action defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. This sale does not represent a discretionary trade by the reporting person.
On August 11, 2022, the reporting person was granted RSUs, of which all 768,133 vested as of September 9, 2023.